CXCR4 over-expression and survival in cancer: A system review and meta-analysis

Oncotarget

Volumn 6, Issue 7, 2015, Pages 5022-5040

  Zhao, Hongli ^a   Guo, Liyuan ^a   Zhao, Hong ^a   Zhao, Jiaxin ^a   Weng, Hao ^b   Zhao, Bin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Cancer; CXCR4; Meta analysis; Prognostic biomarker; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; BL 8040; BORTEZOMIB; CARBOPLATIN; CHEMOKINE RECEPTOR CXCR4; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; LY 2510924; MSX 122; PLERIXAFOR; POL 6326; SUNITINIB; TG 0054; ULOCUPLUMAB; UNCLASSIFIED DRUG; CXCR4 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; AGE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ESOPHAGUS CANCER; FOLLICULAR LYMPHOMA; FOLLOW UP; GALLBLADDER CANCER; GEOGRAPHIC DISTRIBUTION; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; RISK FACTOR; SMALL CELL LUNG CANCER; SOLID TUMOR; SURVIVAL TIME; SYSTEMATIC REVIEW; BIOSYNTHESIS; DISEASE FREE SURVIVAL; METABOLISM; NEOPLASM; SURVIVAL ANALYSIS;

DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS; RECEPTORS, CXCR4; SURVIVAL ANALYSIS;

EID: 84924943548     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3217     Document Type: Article

References (104)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90.
2. Debnath B, Xu S, Grande F, Garofalo A and Neamati N. Small molecule inhibitors of CXCR4. Theranostics. 2013; 3(1):47-75.
3. Caruz A, Samsom M, Alonso JM, Alcami J, Baleux F, Virelizier JL, Parmentier M and Arenzana-Seisdedos F. Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett. 1998; 426(2):271-278.
4. Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf DJ, Zhang J, Ratajczak J and Ratajczak MZ. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 2004; 35(3):233-245.
5. Saini V, Marchese A and Majetschak M. CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. The Journal of biological chemistry. 2010; 285(20):15566-15576.
6. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. The Lancet Oncology. 2013; 14(6):e218-228.
7. Zlotnik A. New insights on the role of CXCR4 in cancer metastasis. The Journal of pathology. 2008; 215(3):211-213.
8. Minamiya Y, Saito H, Takahashi N, Ito M, Imai K, Ono T, Motoyama S and Ogawa J. Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. Lung cancer. 2010; 68(3):466-471.
9. Popple A, Durrant LG, Spendlove I, Rolland P, Scott IV, Deen S and Ramage JM. The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer. British journal of cancer. 2012; 106(7):1306-1313.
10. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC and Cristofanilli M. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol. 2006; 17(6):945-951.
11. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R and Basik M. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat. 2006; 97(3):275-283.
12. Ahn JY, Seo K, Weinberg OK and Arber DA. The prognostic value of CXCR4 in acute myeloid leukemia. Appl Immunohistochem Mol Morphol. 2013; 21(1):79-84.
13. Bao L, Lai Y, Liu Y, Qin Y, Zhao X, Lu X, Jiang Q, Lu J and Huang X. CXCR4 is a good survival prognostic indicator in multiple myeloma patients. Leuk Res. 2013; 37(9):1083-1088.
14. Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M and Medeiros LJ. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 2007; 109(6):1152-1156.
15. Konoplev S, Lin P, Yin CC, Lin E, Nogueras Gonzalez GM, Kantarjian HM, Andreeff M, Medeiros LJ and Konopleva M. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013; 13(6):686-692.
16. Rombouts EJ, Pavic B, Lowenberg B and Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood. 2004; 104(2):550-557.
17. Spoo AC, Lubbert M, Wierda WG and Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007; 109(2):786-791.
18. Zhang Y, Guo Q, Zhao H, Zhao D, Wu X, Zhao W, Wang Y, Xia B and Da W. Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome. Med Oncol. 2013; 30(1):341.
19. Holm NT, Byrnes K, Li BD, Turnage RH, Abreo F, Mathis JM and Chu QD. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res. 2007; 141(1):53-59.
20. Mirisola V, Zuccarino A, Bachmeier BE, Sormani MP, Falter J, Nerlich A and Pfeffer U. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival. Eur J Cancer. 2009; 45(14):2579-2587.
21. Chu QD, Panu L, Holm NT, Li BD, Johnson LW and Zhang S. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. J Surg Res. 2010; 159(2):689-695.
22. Chu QD, Holm NT, Madumere P, Johnson LW, Abreo F and Li BD. Chemokine receptor CXCR4 overexpression predicts recurrence for hormone receptor-positive, node-negative breast cancer patients. Surgery. 2011; 149(2):193-199.
23. Blot E, Laberge-Le Couteulx S, Jamali H, Cornic M, Guillemet C, Duval C, Hellot MF, Pille JY, Picquenot JM and Veyret C. CXCR4 membrane expression in node-negative breast cancer. Breast J. 2008; 14(3):268-274.
24. Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada N, Arriagada R, Hortobagyi GN, Hung MC, Pusztai L, Delaloge S, Michiels S and Cristofanilli M. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist. 2009; 14(12):1182-1188.
25. Holm NT, Abreo F, Johnson LW, Li BD and Chu QD. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC). Breast Cancer Res Treat. 2009; 113(2):293-299.
26. Hassan S, Ferrario C, Saragovi U, Quenneville L, Gaboury L, Baccarelli A, Salvucci O and Basik M. The inflfluence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. Am J Pathol. 2009; 175(1):66-73.
27. Mizell J, Smith M, Li BD, Ampil F and Chu QD. Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study. Ann Surg Oncol. 2009; 16(10):2711-2716.
28. Liu Y, Ji R, Li J, Gu Q, Zhao X, Sun T, Wang J, Du Q and Sun B. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J Exp Clin Cancer Res. 2010; 29:16.
29. Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN and Cristofanilli M. Expression of growth factor and chemokine receptors: new insights in the biology of inflflammatory breast cancer. Ann Oncol. 2007; 18(6):1021-1029.
30. Chen HW, Du CW, Wei XL, Khoo US and Zhang GJ. Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer. Curr Mol Med. 2013; 13(3):410-416.
31. Chen SF, Du CW, Yang P, Zhang HW, Kwan M and Zhang GJ. The molecular and clinicopathologic characteristics of bilateral breast cancer. Sci Rep. 2013; 3:2590.
32. Hiller DJ, Meschonat C, Kim R, Li BD and Chu QD. Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer. Surgery. 2011; 150(3):459-465.
33. Parker CC, Kim RH, Li BD and Chu QD. The chemokine receptor CXCR4 as a novel independent prognostic marker for node-positive breast cancer patients. J Surg Oncol. 2012; 106(4):393-398.
34. Yu S, Wang X, Liu G, Zhu X and Chen Y. High level of CXCR4 in triple-negative breast cancer specimens associated with a poor clinical outcome. Acta Med Okayama. 2013; 67(6):369-375.
35. D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV and Scala S. A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. International journal of cancer Journal international du cancer. 2014; 135(2):379-390.
36. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ and Hoon DS. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. Journal of clinical oncology: offificial journal of the American Society of Clinical Oncology. 2005; 23(12):2744-2753.
37. Liu Y, Zhou Y, Feng X, Yang P, Yang J, An P, Wang H, Ye S, Yu C, He Y and Luo H. Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer. Genes Chromosomes Cancer. 2014; 53(4):358-365.
38. Ottaiano A, Franco R, Aiello Talamanca A, Liguori G, Tatangelo F, Delrio P, Nasti G, Barletta E, Facchini G, Daniele B, Di Blasi A, Napolitano M, Ierano C, Calemma R, Leonardi E, Albino V, et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clinical cancer research: an offificial journal of the American Association for Cancer Research. 2006; 12(9):2795-2803.
39. Saigusa S, Toiyama Y, Tanaka K, Yokoe T, Okugawa Y, Kawamoto A, Yasuda H, Inoue Y, Miki C and Kusunoki M. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. Ann Surg Oncol. 2010; 17(8):2051-2058.
40. Speetjens FM, Liefers GJ, Korbee CJ, Mesker WE, van de Velde CJ, van Vlierberghe RL, Morreau H, Tollenaar RA and Kuppen PJ. Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients. Cancer Microenviron. 2009; 2(1):1-7.
41. Zhang NH, Li J, Li Y, Zhang XT, Liao WT, Zhang JY, Li R and Luo RC. Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients. Exp Ther Med. 2012; 3(6):973-982.
42. Gockel I, Schimanski CC, Heinrich C, Wehler T, Frerichs K, Drescher D, von Langsdorff C, Domeyer M, Biesterfeld S, Galle PR, Junginger T and Moehler M. Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma. BMC Cancer. 2006; 6:290.
43. Kaififi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K and Izbicki JR. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst. 2005; 97(24):1840-1847.
44. Koishi K, Yoshikawa R, Tsujimura T, Hashimoto-Tamaoki T, Kojima S, Yanagi H, Yamamura T and Fujiwara Y. Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer. World journal of gastroenterology: WJG. 2006; 12(47):7585-7590.
45. Lu CL, Ji Y, Ge D, Guo J and Ding JY. The expression of CXCR4 and its relationship with matrix metalloproteinase-9/vascular endothelial growth factor in esophageal squamous cell cancer. Dis Esophagus. 2011; 24(4):283-290.
46. Lu CL, Guo J, Gu J, Ge D, Hou YY, Lin ZW and Ding JY. CXCR4 heterogeneous expression in esophageal squamous cell cancer and stronger metastatic potential with CXCR4-positive cancer cells. Dis Esophagus. 2014; 27(3):294-302.
47. Sasaki K, Natsugoe S, Ishigami S, Matsumoto M, Okumura H, Setoyama T, Uchikado Y, Kita Y, Tamotsu K, Hanazono K, Owaki T and Aikou T. Expression of CXCL12 and its receptor CXCR4 in esophageal squamous cell carcinoma. Oncology reports. 2009; 21(1):65-71.
48. Zhang L, Ye SB, Ma G, Tang XF, Chen SP, He J, Liu WL, Xie D, Zeng YX and Li J. The expressions of MIF and CXCR4 protein in tumor microenvironment are adverse prognostic factors in patients with esophageal squamous cell carcinoma. J Transl Med. 2013; 11:60.
49. Fanelli MF, Chinen LT, Begnami MD, Costa WL, Jr., Fregnami JH, Soares FA and Montagnini AL. The inflfluence of transforming growth factor-alpha, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology. 2012; 61(2):153-161.
50. He H, Wang C, Shen Z, Fang Y, Wang X, Chen W, Liu F, Qin X and Sun Y. Upregulated expression of C-X-C chemokine receptor 4 is an independent prognostic predictor for patients with gastric cancer. PloS one. 2013; 8(8):e71864.
51. Kwak MK, Hur K, Park DJ, Lee HJ, Lee HS, Kim WH, Lee KU, Choe KJ and Yang HK. Expression of chemokine receptors in human gastric cancer. Tumour Biol. 2005; 26(2):65-70.
52. Lee HJ, Kim SW, Kim HY, Li S, Yun HJ, Song KS, Kim S and Jo DY. Chemokine receptor CXCR4 expression, function, and clinical implications in gastric cancer. International journal of oncology. 2009; 34(2):473-480.
53. Ying J, Xu Q, Zhang G, Liu B and Zhu L. The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis. Med Oncol. 2012; 29(3):1716-1722.
54. Albert S, Hourseau M, Halimi C, Serova M, Descatoire V, Barry B, Couvelard A, Riveiro ME, Tijeras-Raballand A, de Gramont A, Raymond E and Faivre S. Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue. Oral Oncol. 2012; 48(12):1263-1271.
55. Almofti A, Uchida D, Begum NM, Tomizuka Y, Iga H, Yoshida H and Sato M. The clinicopathological signifificance of the expression of CXCR4 protein in oral squamous cell carcinoma. International journal of oncology. 2004; 25(1):65-71.
56. Clatot F, Picquenot JM, Choussy O, Gouerant S, Moldovan C, Schultheis D, Cornic M, Francois A, Blot E and Laberge-Le-Couteulx S. Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma. Oral Oncol. 2011; 47(11):1062-1068.
57. Katayama A, Ogino T, Bandoh N, Nonaka S and Harabuchi Y. Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma. Clinical cancer research: an offificial journal of the American Association for Cancer Research. 2005; 11(8):2937-2946.
58. Lee JI, Jin BH, Kim MA, Yoon HJ, Hong SP and Hong SD. Prognostic signifificance of CXCR-4 expression in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 107(5):678-684.
59. Segawa Y, Oda Y, Yamamoto H, Shiratsuchi H, Hirakawa N, Komune S and Tsuneyoshi M. Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma. Oncology reports. 2009; 21(5):1197-1202.
60. Wang N, Wu QL, Fang Y, Mai HQ, Zeng MS, Shen GP, Hou JH and Zeng YX. Expression of chemokine receptor CXCR4 in nasopharyngeal carcinoma: pattern of expression and correlation with clinical outcome. J Transl Med. 2005; 3:26.
61. Chen D, Gassenmaier M, Maruschke M, Riesenberg R, Pohla H, Stief CG, Zimmermann W and Buchner A. Expression and prognostic signifificance of a comprehensive epithelial-mesenchymal transition gene set in renal cell carcinoma. J Urol. 2014; 191(2):479-486.
62. An H, Xu L, Zhu Y, Lv T, Liu W, Liu Y, Liu H, Chen L, Xu J and Lin Z. High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma. British journal of cancer. 2014; 110(9):2261-2268.
63. D'Alterio C, Consales C, Polimeno M, Franco R, Cindolo L, Portella L, Cioffifi M, Calemma R, Marra L, Claudio L, Perdona S, Pignata S, Facchini G, Carteni G, Longo N, Pucci L, et al. Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets. 2010; 10(7):772-781.
64. Li X, Huang Y, Xia J, Chen N, Wei Q, Zhang P, Shen PF, Wang J and Zeng H. CXCR4 expression in patients with high-risk locally advanced renal cell carcinoma can independently predict increased risk of disease progression and poor overall survival. Asian Pacifific journal of cancer prevention: APJCP. 2011; 12(12):3313-3318.
65. Li G, Badin G, Zhao A, Gentil-Perret A, Tostain J, Peoc'h M and Gigante M. Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma. Histol Histopathol. 2013; 28(9):1217-1222.
66. Wang L, Chen W, Gao L, Yang Q, Liu B, Wu Z, Wang Y and Sun Y. High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma. World journal of surgical oncology. 2012; 10:212.
67. Otsuka S, Klimowicz AC, Kopciuk K, Petrillo SK, Konno M, Hao D, Muzik H, Stolte E, Boland W, Morris D, Magliocco AM and Bebb DG. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. Journal of thoracic oncology: offificial publication of the International Association for the Study of Lung Cancer. 2011; 6(7):1169-1178.
68. Reckamp KL, Figlin RA, Burdick MD, Dubinett SM, Elashoff RM and Strieter RM. CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer. 2009; 9:213.
69. Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, Khayat D, Le Chevalier T and Soria JC. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 2004; 15(4):613-617.
70. Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA, Rengifo T, Sica GL, Port JL, Lee PC, Paul S, Altorki NK and Saqi A. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg. 2009; 137(3):615-621.
71. Wang M, Chen GY, Song HT, Hong X, Yang ZY and Sui GJ. Signifificance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer. Exp Ther Med. 2011; 2(3):517-522.
72. Al Zobair AA, Al Obeidy BF, Yang L, Yang C, Hui Y, Yu H, Zheng F, Yang G, Xie C, Zhou F and Zhou Y. Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer. Oncology reports. 2013; 29(4):1524-1532.
73. Franco R, Cantile M, Scala S, Catalano E, Cerrone M, Scognamiglio G, Pinto A, Chiofalo MG, Caraco C, Anniciello AM, Abbruzzese A, Caraglia M and Botti G. Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. Cancer biology & therapy. 2010; 9(6):423-429.
74. Longo-Imedio MI, Longo N, Trevino I, Lazaro P and Sanchez-Mateos P. Clinical signifificance of CXCR3 and CXCR4 expression in primary melanoma. International journal of cancer Journal international du cancer. 2005; 117(5):861-865.
75. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G and Castello G. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clinical cancer research: an offificial journal of the American Association for Cancer Research. 2005; 11(5):1835-1841.
76. Scala S, Ierano C, Ottaiano A, Franco R, La Mura A, Liguori G, Mascolo M, Staibano S, Ascierto PA, Botti G, De Rosa G and Castello G. CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunol Immunother. 2007; 56(10):1589-1595.
77. Jiang YP, Wu XH, Shi B, Wu WX and Yin GR. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol. 2006; 103(1):226-233.
78. Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Ojima Y, Nakamura K, Hongo A and Hiramatsu Y. Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol. 2007; 18(1):70-76.
79. Li J, Jiang K, Qiu X, Li M, Hao Q, Wei L, Zhang W, Chen B and Xin X. Overexpression of CXCR4 is signifificantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer. BMB Rep. 2014; 47(1):33-38.
80. Oda Y, Ohishi Y, Basaki Y, Kobayashi H, Hirakawa T, Wake N, Ono M, Nishio K, Kuwano M and Tsuneyoshi M. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer science. 2007; 98(7):1020-1026.
81. Pils D, Pinter A, Reibenwein J, Alfanz A, Horak P, Schmid BC, Heflfler L, Horvat R, Reinthaller A, Zeillinger R and Krainer M. In ovarian cancer the prognostic inflfluence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. British journal of cancer. 2007; 96(3):485-491.
82. Sekiya R, Kajiyama H, Sakai K, Umezu T, Mizuno M, Shibata K, Yamamoto E, Fujiwara S, Nagasaka T and Kikkawa F. Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary. Hum Pathol. 2012; 43(6):904-910.
83. Shiozaki T, Tabata T, Ma N, Yamawaki T, Motohashi T, Kondo E, Tanida K, Okugawa T and Ikeda T. Association of CXC chemokine receptor type 4 expression and clinicopathologic features in human vulvar cancer. Int J Gynecol Cancer. 2013; 23(6):1111-1117.
84. Gebauer F, Tachezy M, Effenberger K, von Loga K, Zander H, Marx A, Kaififi JT, Sauter G, Izbicki JR and Bockhorn M. Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J Surg Oncol. 2011; 104(2):140-145.
85. Marechal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, Closset J, Deviere J, Salmon I and Van Laethem JL. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. British journal of cancer. 2009; 100(9):1444-1451.
86. Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y and Fuse H. Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer science. 2008; 99(3):539-542.
87. Jung SJ, Kim CI, Park CH, Chang HS, Kim BH, Choi MS and Jung HR. Correlation between Chemokine Receptor CXCR4 Expression and Prognostic Factors in Patients with Prostate Cancer. Korean J Urol. 2011; 52(9):607-611.
88. Xiang ZL, Zeng ZC, Tang ZY, Fan J, Zhuang PY, Liang Y, Tan YS and He J. Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer. 2009; 9:176.
89. Yopp AC, Shia J, Butte JM, Allen PJ, Fong Y, Jarnagin WR, DeMatteo RP and D'Angelica MI. CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2012; 19 Suppl 3:S339-346.
90. Lin F, Zheng SE, Shen Z, Tang LN, Chen P, Sun YJ, Zhao H and Yao Y. Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma. Med Oncol. 2011; 28(2):649-653.
91. Oda Y, Tateishi N, Matono H, Matsuura S, Yamamaoto H, Tamiya S, Yokoyama R, Matsuda S, Iwamoto Y and Tsuneyoshi M. Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. International journal of cancer Journal international du cancer. 2009; 124(8):1852-1859.
92. Yao X, Zhou L, Han S and Chen Y. High expression of CXCR4 and CXCR7 predicts poor survival in gallbladder cancer. J Int Med Res. 2011; 39(4):1253-1264.
93. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG and Walenkamp AM. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013; 49(1):219-230.
94. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005; 438(7069):820-827.
95. Wong D and Korz W. Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside. Clinical cancer research: an offificial journal of the American Association for Cancer Research. 2008; 14(24):7975-7980.
96. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J and Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100.
97. Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16.
98. Wu J, Wu X, Liang W, Chen C, Zheng L and An H. Clinicopathological and prognostic signifificance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a meta-analysis. Tumour Biol. 2014; 35(4):3709-3715.
99. Liu CF, Liu SY, Min XY, Ji YY, Wang N, Liu D, Ma N, Li ZF and Li K. The prognostic value of CXCR4 in ovarian cancer: a meta-analysis. PloS one. 2014; 9(3):e92629.
100. Zhang Z, Ni C, Chen W, Wu P, Wang Z, Yin J, Huang J and Qiu F. Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer. 2014; 14:49.
101. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-605.
102. Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-560.
103. DerSimonian R and Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-188.
104. Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-1101.